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Abstract
Background: Renal cell carcinoma (RCC) has multiple symptoms stemming from disease and
treatments. There are few validated scales for evaluating RCC symptoms.
Methods: A national cross-sectional study of adult RCC patients was conducted from October to
December 2003 to define patient-reported RCC symptomology. Participants were asked open-
ended questions regarding their signs and symptoms and completed an 86-item pilot questionnaire
of physical and psychological symptoms. Patients were asked to rate the relevancy and clarity of
each pilot question using a 5-point Likert scale. Subsequent open-ended caregiver interviews and a
provider panel relevance ranking contributed additional information.
Results: The average age of the participants (n = 31) was 55 years; 55% of patients were male, 74%
had attended college, and 97% were Caucasian. The five most frequent symptoms among localized-
stage patients (n = 14) were irritability (79%), pain (71%), fatigue (71%), worry (71%), and sleep
disturbance (64%). Among metastatic patients (n = 17), the five most frequent symptoms were
fatigue (82%), weakness (65%), worry (65%), shortness of breath (53%), and irritability (53%). More
than 50% of localized and metastatic-stage patients reported pain, weakness, fatigue, sleep
disturbance, urinary frequency, worry, and mood disorders as being moderately to highly relevant.
Conclusion:  A brief, self-administered RCC Symptom Index was created that captures the
relevant signs and symptoms of both localized and metastatic patients. Pending additional content
validation, the Index can be used to assess the signs and symptoms of RCC and the clinical benefit
resulting from RCC treatment.
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Background
Renal cell carcinoma (RCC) is the most common type of
kidney cancer and comprises about 85% of all kidney
tumors [1,2]. Approximately 30,600 patients are newly
diagnosed each year with RCC in the United States (US),
and an estimated 12,000 deaths occur annually from this
malignancy [3]. At the time of diagnosis, patients are
often in advanced stages of the disease, with 40% to 50%
of patients presenting with unresectable or metastatic dis-
ease [4,5]. Treatment with biological agents, such as inter-
leukin-2 alone or in combination with interferon-alpha,
has demonstrated the highest survival benefit. These ther-
apeutic approaches remain limited due to minimal pro-
longation of life and severe toxicities associated with
treatment [6,7]. Despite recent advances in treatment
options and the emergence of several experimental thera-
pies, the prognosis for long-term survival remains low,
with or without therapy. The 5-year cumulative survival
rate of these patients ranges from 5% to 10% [5].
Given the toxic side effects associated with current treat-
ment and the poor survival prognosis among patients
with RCC, health-related quality of life (HRQL) has
become an important medical outcome among this
patient population. A number of clinical studies among
patients with RCC have assessed symptoms and HRQL [8-
19]. Along with survival, the FDA oncology division con-
siders symptom improvement to be one of the primary
measures of clinical benefit [20]. Consistent with other
tumors [21], there is some evidence linking survival and
symptoms in RCC that suggests an association between
tumor and symptom burden [22-25]. A number of general
cancer questionnaires have been used to evaluate RCC
symptoms or HRQL from the patient perspective, includ-
ing the Functional Assessment of Cancer Therapy-Biologic
Response Modifier (FACT-BRM) [26], the Rotterdam
Symptom Checklist [27], and the European Organization
for Research and Treatment of Cancer HRQL survey
(EORTC QLQ-C30) [28]. While these questionnaires were
designed to assess HRQL among cancer patients, these
measures are not specific to RCC or kidney cancer overall.
At the time of this study there was no published question-
naire developed to capture the symptoms specific to RCC
or kidney cancer patients. While a number of general can-
cer symptom scales exist, their use among RCC patients
may add to the respondent burden of patient-reported
outcomes by asking about symptoms and problems that
may not be relevant to this population. In addition, exist-
ing cancer questionnaires may not adequately capture all
the patient symptoms associated with the disease. The
purpose of this study was to identify the appropriate con-
tent for a disease-specific questionnaire for the assessment
of symptom burden in RCC patients.
Our conceptual model for a RCC Symptom Index (Index)
incorporated signs and symptoms, as classically defined
[29,30]. Questions about the impact of these signs and
symptoms on the activities of daily living were also
included when clearly linked by the patient or physician
to the disease. In this way, symptom-driven functional
impairment was an indirect measure of symptom burden
[31]. While the conceptual framework of a HRQL ques-
tionnaire is important, so too are its performance charac-
teristics if it is to inform treating physicians and health
policy makers about the clinical benefit of treatment. In
this regard, we were guided by scientific conventions for
HRQL questionnaire development [32,33].
To facilitate the standardization of HRQL assessment in
cancer and promote HRQL comparison across treatment
modalities, the authors used an established framework for
questionnaire development: the Functional Assessment of
Chronic Illness Therapy (FACIT) model [34]. The FACIT
model focuses on the frequency of disease manifestations
over a 7-day recall period. A short recall period is needed
to ensure accurate patient recall of the symptom experi-
ence while avoiding the bias that could result from mem-
ories based on any one moment, since symptoms wax and
wane. The FACIT model measures symptom frequency,
rather than intensity or duration, which are two other key
aspects of symptom assessment. Two of the most com-
mon kidney cancer symptoms, fatigue and pain, have
demonstrated a close association between symptom fre-
quency and intensity, as well as functional impact when
using short patient recall periods [22,30,35-41]. Conse-
quently, the 7-day recall of RCC symptom frequency is a
meaningful measure of intensity, as well as functional
impact, and was considered appropriate for the Index.
Methods
Study design
A triangulation or convergence approach was used for
content development of the Index [42]. Multiple sources
of information, including qualitative and quantitative
data, were pooled in an inclusive process that held patient
opinion as primary for the identification of Index ques-
tions (Figure 1). Caregivers or providers could add items
to the questionnaire, but not remove any items identified
by patients as clear and relevant. Any question that was a
source of investigator disagreement was added to the
Index, with the understanding that subsequent construct
validation research would clarify the performance of vari-
ous items.
The first step in this process was a narrative review of the
quality of life literature for RCC or kidney cancer patients.
This literature review was the basis for constructing a pilot
Index comprising relevant items from established cancer
quality of life questionnaires. The second step was aHealth and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
Page 3 of 12
(page number not for citation purposes)
national, cross-sectional, semi-structured telephone inter-
view of adult RCC patients and their caregivers conducted
from October to December 2003. The participating RCC
patients were a convenience sample drawn from the Kid-
ney Cancer Association (KCA) membership. The patient
interviews began with a series of open-ended questions
about their RCC signs and symptoms and ended with the
patient completion of a self-administered pilot question-
naire. The qualitative component of the caregiver inter-
views were similarly conducted, but the evaluation of the
pilot questionnaire items was not included in their tele-
phone interviews.
The pilot questionnaire was revised using patient and car-
egiver interview findings and then evaluated by physicians
and nurses who had experience with the RCC population
(Figure 1). Descriptive statistics were used to characterize
the socio-demographic and clinical characteristics of the
RCC patient sample. Questions for the Index were
selected based on the 1) frequency distributions from the
patient relevance rankings, 2) patient comments on item
clarity, 3) responses from open-ended patient and car-
egiver questions, 4) provider relevance rankings, and 5)
investigator assessment of item clarity, redundancy and
likely disease, rather than treatment, origin. Additional
details on each step are provided in the following sections.
Institutional Review Board approval was obtained to com-
ply with human participant research requirements prior
to study initiation. All participants gave written, informed
consent before beginning study procedures.
Literature review and pilot questionnaire creation
The PubMed literature database was used to identify
potentially important signs, symptoms, and related HRQL
issues among localized and metastatic RCC patients. The
search selected RCC clinical studies that included HRQL,
including those with only baseline symptom assessment.
Studies that were not available in English, non-human in
test subject, or included fewer than 20 patients were
excluded from the literature review.
A pilot questionnaire was constructed using items from
existing cancer HRQL questionnaires. Questions were
selected for the pilot Index if the items specifically
addressed the RCC signs and symptoms, along with asso-
ciated functioning issues, that were identified in the liter-
ature review. An item's relevance to a RCC patient was
based on their response to a standard Likert 5-level scale:
not at all (0), a little bit (1), somewhat (2), quite a bit (3),
very much (4).
Patient interviews
The patient sample was recruited through the KCA, a non-
profit membership organization based in Chicago, IL. The
KCA comprises patients, family members, physicians,
researchers, and other health professionals involved in
kidney cancer care. The KCA provides information on the
latest research in kidney cancer and acts as a patient advo-
cate with the federal government, insurance companies,
and employers. Postcards were sent to 1,500 KCA mailing
list members to recruit study participants. Potential study
participants who responded by telephone to the postcard
invitation were screened via telephone using a standard-
ized form to ensure that participants met all entry criteria.
To be eligible, participants 1) had a diagnosis of RCC or
kidney cancer; 2) were 21 years of age or older; 3) were
either previously treated or currently being treated for this
condition; and 4) were able to speak and understand Eng-
lish. Study enrollment was stratified on self-reported
localized or metastatic disease since Health Insurance
Portability and Accountability Act of 1996 (HIPAA) regu-
lations made access to patient medical charts difficult, fur-
ther compounded by the geographically-dispersed nature
of this national patient cohort. A variety of standard
demographic and clinical questions were included in the
interview to characterize the study population.
A patient sample of 30 was considered adequate for this
content validation research based on qualitative research
practices, as well as investigator experience [42]. RCC
patients were mailed the pilot questionnaire in advance,
to be completed during a scheduled telephone interview
and later returned by mail. Professional research staff
trained in qualitative interviewing techniques conducted
the interviews. Patients were first asked open-ended ques-
tions about RCC symptoms they had experienced and
RCC Symptom Index Development Process Figure 1
RCC Symptom Index Development Process.
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how their daily life had been affected by these symptoms.
This was done prior to completing the pilot questionnaire
to maximize the discovery of new signs and symptoms
that had not previously appeared in the literature. In addi-
tion, this minimized any content biasing the pilot ques-
tionnaire may introduce. In the open-ended portion of
the interview patients were asked about their symptom
experience at the time of initial diagnosis, prior to diagno-
sis, and after treatment. Patients were then asked to com-
plete the pilot questionnaire. Patients who had
undergone a nephrectomy were asked to use a recall
period "just prior to surgery" to capture relevant symp-
toms since patients might become asymptomatic after
their surgery [43-45].
After completing the pilot questionnaire, patients were
asked about their overall assessment of the pilot question-
naire. The structured dialogue was designed to elicit the
items most relevant to RCC patients since the pilot ques-
tionnaire was based on a synthesis of validated cancer
HRQL scales. Besides rating the relevance of pilot ques-
tionnaire items, patients were asked to identify items that
were unclear or confusing using the same 5-level Likert
scale applied to relevance ranking. For multiple items that
addressed the same or similar concept, patients were
asked to identify the most clear and understandable item
(i.e., the item that best represents or describes how they
feel). Finally, patients were asked if there were any other
signs, symptoms or related health issues they thought
were important that were not included in the pilot ques-
tionnaire.
Caregiver interviews
A convenience sample of caregivers was recruited from the
participating RCC patients to gain additional information
on the symptom burden they had observed. RCC patients
were asked at the conclusion of their semi-structured
interviews whether they had a family member or friend
who would be willing to participate in a telephone inter-
view. Potential caregiver study participants were screened
over the telephone and had to meet the following eligibil-
ity criteria: 1) 21 years of age or older; 2) a family member
or friend who sees or speaks to the RCC study participant
at least 4 times a week or resides with him or her; and 3)
provides care to RCC study participant on a self-reported,
consistent basis. As with the patients, caregiver interviews
focused on the symptoms that the person they cared for
had experienced before, during, and after treatment. Car-
egivers were asked about the impact of these symptoms
on the RCC patient's daily life, to describe the physical
and emotional symptoms that bothered the RCC patient
the most before and after treatment, and the changes that
they noticed in signs, symptoms, and functioning once
treatment began.
Index item generation
A content analysis approach was used to evaluate the
qualitative data collected from interviews. Three research-
ers independently reviewed the interview transcripts of
RCC patients and caretakers to identify and summarize
key themes, recurrent words, and specific health issues.
This summary was used to identify the signs and symp-
toms relevant to patients with RCC.
Descriptive statistics (frequency of endorsement of each
response option) were used to examine the patient rele-
vance rankings of the pilot questionnaire by disease sta-
tus: localized or metastatic. Sensitivity analysis explored
different cut-points in item relevance for all patients as
well as clinical subsets. Item exclusion was based on sev-
eral criteria: 1) patient ratings of item relevancy; 2) under-
standability of items; and 3) item redundancy. Items
identified by 50% or more of respondents as irrelevant
(rating of 0 or 1) were deleted, as were items reported by
10% or more of patients as "unclear." Those questions
rated by patients as "somewhat" to "very much" relevant
were selected from the pilot questionnaire for inclusion in
the Index.
Provider assessment
The resulting initial Index was subsequently reviewed for
comprehensiveness and clinical relevance by a panel of
healthcare providers who were working in kidney cancer
care. These experts were identified based on their familiar-
ity with HRQL issues in kidney cancer and RCC patients.
Each member of the panel reviewed the Index and rated
the relevance of each item on a scale ranging from 0 (not
at all relevant, delete) to 4 (highly relevant, must be
included). In addition, clinicians were asked to note if any
item was unclear and to provide suggested changes. Open-
ended questions were also included to capture other
important signs or symptoms that did not appear in the
draft Index. Provider ratings of symptom relevance influ-
enced the item list through the inclusion of questions, but
never overruled patient valuation.
Final item review
Study investigators assessed the Index item list after the
provider panel evaluation to ensure that all the appropri-
ate domains and items were adequately represented in the
final Index. Additional items from the other sources: liter-
ature review, provider panel and caregiver observations
were also considered for inclusion at this point. Questions
that met the Index inclusion criteria for either the local or
metastatic sub-populations of RCC patients were included
without any weighing of Index domains.Health and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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Results
Literature review and pilot questionnaire generation
Twelve studies were selected for review, including two ran-
domized controlled studies, two non-randomized com-
parative trials, and eight observational studies (Table 1).
Based on findings from these studies, the most frequently
reported symptoms among RCC patients include fatigue,
weakness, pain, lack of appetite, nausea, dyspnea, flu-like
symptoms, diarrhea, constipation, headache, and dry
mouth. Results also suggest that patient HRQL is affected,
particularly with respect to physical functioning, psycho-
logical impairment (depression, anxiety, irritability),
sleep, social functioning, and role activities.
The pilot questionnaire resulting from this process was 86
items in length and covered 20 domains or health issues
Table 1: Literature Review Summary Results for RCC Symptoms or HRQL
Citation Number Study Design Instrument Results of Symptom and/or HRQL 
assessment
MRC Renal Cancer 1999 [8] N = 335 Randomized Rotterdam Symptom Checklist Most frequent symptoms at 4 weeks: tired (57%), 
lack of energy (53%), lack of appetite (33%), dry 
mouth (27%), nausea (15%), shivering (13%), 
heartburn (12%)
Motzer et al. 2000 [9] N = 284 Randomized FACT-BRM QOL decreased from baseline to 8 weeks for 
treatment arms. Item analysis of FACT-BRM 
indicates items that address the following likely to 
be important at baseline: energy, pain, sex life, 
overall well-being, sleep, fatigue, appetite, energy, 
weakness (Cella D, personal communication, 
September 2003)
Capuron et al. 2001 [10] N = 33 Non-randomized MADRS Positive correlation between depressive 
symptoms and the variation in the cytokine levels 
in the first week of therapy.
Heinzer et al. 1999 [11] N = 20 Non-randomized EORTC-QLQ-30 Most frequent symptoms: fatigue (29%), nausea 
(23%), cough (16%).
Atzpodien et al. 2003 [12] N = 22 Observational SF-36 EORTC-QLQ-30 Significant worsening in physical, social, and role 
functioning. Significant worsening in symptoms of 
appetite loss, nausea/vomiting, sleep disturbance, 
diarrhea, pain
Bukowski et al. 2002 [13] N = 70 Observational AE events Most frequently reported adverse events over 1 
year: fatigue (38%), anorexia (34%), pain (34%), 
headache (31%), myalgia (28%), weight loss (28%), 
nausea (24%), alopecia (21%), coughing: (21%), 
dyspnea (21%), fever (21%), rigors (21%)
Cohen et al. 2002 [14] N = 36 Observational SF-36 Changes from baseline to 3 weeks indicate 
improvement in physical functioning, role 
limitations (physical), bodily pain, vitality, and 
social functioning
Joffe et al. 1996 [15] N = 55 Observational Rotterdam Symptom Checklist During 8-week treatment cycle, significant 
worsening in symptoms: loss of appetite, dry 
mouth, lack of energy, feeling nervous, lack of 
sexual interest, shivering, nausea, tiredness
Naglieri et al. 2002 [16] N = 42 Observational Graded toxicities Total prevalence: fatigue (100%), cutaneous 
erythema (100%), fever (76%), anemia (10%), 
hypotension (5%), nausea/vomitting (2%), fluid 
retention (2%)
Shamash et al. 2003 [17] N = 33 Observational EORTC Mean baseline scores indicate greatest impairment 
in pain, sleep, weakness, daily activities, tired, 
leisure/social
Stark et al. 2002 [18] N = 178 Observational HAD-A EORTC-QLQ-30 Patients diagnosed with anxiety had higher scores 
for symptoms of fatigue, nausea, insomnia, 
appetite loss, constipation, diarrhea
Whitehead et al. 2002 [19] N = 37 Observational Graded toxicity Most common side effects (% with any grade 
toxicity): nausea/vomiting/diarrhea: 88%, 
headache/pain: 82%, malaise/fatigue/lethargy: 78%, 
fever/chills: 57%, edema: 51%, CNS: 43%, anemia/
bleeding: 33%, myalgia/arthralgia: 31%, renal: 29%, 
pulmonary: 27%, rash/urticaria: 24%, 
hypertension: 8%, cardiac: 4%, hypotension: 4%Health and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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of interest (Figure 2). Questions were included from the
Functional Assessment of Cancer Therapy-General (FACT-
General) [46] as well as items from the prostate cancer
(FACT-P) [47], lung cancer (FACT-L) [48], fatigue (FACT-
F) [49,50], hepatobiliary cancer (FACT-HEP) [51], and
biological response modifier (FACT-BRM) [26] FACT sub-
scales. Items were also included from the European
Organization for Research and Treatment of Cancer
HRQL survey, the EORTC-QLQ-C30 [28].
Patient and caregiver cohort selection
Patient entry into the study sample was stopped at 162
patients, although inbound telephone calls expressing
interest in the study continued. The first 46 respondents
who were successfully contacted by telephone were
screened for study entry. All but three met eligibility crite-
ria since the criteria were broad and the recruitment proc-
ess closely matched the entry criteria. The first 31 patients
from the pool of 43 who were approached entered into
the study without exception.
Among the RCC patients, 55% (n = 17) were male and
97% (n = 30) were Caucasian. Approximately one-third
(32%, n = 10) of the RCC study sample reported that they
were employed full-time, while the same number (32%, n
= 10) reported that they were disabled, and 26% (n = 8)
were retired. Almost all of the RCC patients had a high
school education or higher, with nearly half (48%) report-
ing a college or postgraduate degree. The year of diagnosis
ranged from 9 years prior to within 1 year of study initia-
tion (Table 2).
Among study patients, 45% (n = 14) reported localized-
staged disease and 55% (n = 17) reported that their cancer
had metastasized. The mean length of time since last treat-
ment was 9 months and 6 months for localized and met-
astatic-staged patients, respectively (Table 3). Of those
with self-reported metastatic disease, 47% (8/17) indi-
cated that their last treatment included biologic agents.
The caregivers (n = 10) in the study had a mean age of 52,
all were Caucasian and half were female. All but one car-
egiver had more than a high school education; 5 were
employed full time (data not shown).
Patient and caregiver interviews
All 31 patients and 10 caregivers were interviewed. Based
on their qualitative responses, the three most common
reasons for seeking medical attention included pain in
abdomen or back area, fatigue, and urinary problems
including hematuria and passing of clots. The onset of
pain varied from sudden onset to ongoing feelings of
pain, with varying levels of pain severity described.
Fatigue was described as "having very little energy,"
"exhausted," and "real severe fatigue." Other symptoms
mentioned less often and classified as being present prior
to diagnosis, included diarrhea, constipation, weight loss,
and nausea. In general, patients with metastatic RCC
focused more on being tired and experiencing noticeable
weight loss than patients with localized-stage RCC when
Pilot RCC Questionnaire Domain Relevance Frequency Figure 2
Pilot RCC Questionnaire Domain Relevance Fre-
quency. Domain relevance was based on patients rating at 
least one item within a sign or symptom domain as "Some-
what" to "Very much" relevant to their lives. Percentages 
listed above each domain use all patients as the denominator 
(localized and metastatic). Not all domains were included 
into the final Index due to the importance rankings of each 
question within the domain.
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Table 2: Demographics of RCC Patients
Characteristic N = 31
Age, mean (SD) 54.6 (11.4)
Gender, n (%)
Male 17 (54.8)
Female 14 (45.2)
Race, n (%)
White 30 (96.8)
Black or African American 1 (3.2)
Employment Status, n (%)
Full-time 10 (32.3)
Part-time 1 (3.2)
Retired 8 (25.8)
Disabled 10 (32.3)
Other 2 (6.5)
Highest Education Level, n (%)
Elementary 0 (0)
High School 6 (19.4)
Some College 8 (25.8)
College degree 9 (29.0)
Postgraduate degree 6 (19.4)
Other 2 (6.5)
RCC spread, n (%)
Localized 14 (45.2)
Metastatic 17 (54.8)
Range of diagnosis year 1994–2003
All data were patient-reported at time of interview. Percentages may 
not equal 100 due to rounding.Health and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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describing the symptoms that led them to seek medical
attention.
While RCC patients felt that their daily and leisure activi-
ties were limited by symptoms, most addressed the emo-
tional experience more than the physical, with emphasis
on depression and worry. This emotional impairment was
due in large part to initial misdiagnoses and continuing
symptoms. Post-treatment, nearly all patients with local-
ized disease mentioned that they still experienced pain
subsequent to a nephrectomy, although the pain severity
had decreased after surgery. Those with metastatic disease
reported flu-like symptoms associated with treatment.
Caregiver interviews closely mirrored patient interviews
with respect to physical symptoms as they related to RCC,
with pain being the predominant symptom. As expected,
there was more divergence between RCC patient and car-
egiver views with respect to the patients' emotional symp-
toms such as depression, although no clear patterns were
apparent.
RCC symptom index
All 31 RCC patients completed and returned the pilot
questionnaire. The symptom profile of these RCC patients
at the domain level using pilot questionnaire data appears
in Figure 2. The five most frequently reported symptoms
for which patients responded either "somewhat," "quite a
bit," or "very much" among localized-staged patients
included items on irritability (79%), pain (71%), fatigue
(71%), worry (71%), and sleep disturbance (64%).
Among metastatic patients, the five most frequently
reported symptoms came from items reporting fatigue
(82%), weakness (65%), worry (65%), shortness of
breath (53%), and irritability (53%). Fewer than 25% of
people with metastatic disease reported "somewhat,
"quite a bit," or "very much" for any single pain item, pos-
sibly due to ongoing pain treatment. More than 50% of
localized and metastatic-staged patients reported pain,
weakness, fatigue, sleep disturbance, urinary frequency,
worry, irritability, and depression as being moderately (a
score of 2 on a scale of 0–4) to highly relevant (score of 3
or 4 on a scale of 0–4).
The Index item list was reduced from the initial 86 items
based on patient and caregiver interviews along with
patient relevance rankings. Only one item was deemed
"not relevant" based on a mean score of "1" or less on a
scale of 0–4 for both localized- and metastatic-staged
patients. An additional 12 items were reported by 10% or
more of study patients as difficult to understand and were
therefore deleted. Items that met inclusion criteria were
retained (Table 4). The provider panel of five physicians
and five nurses confirmed all items that remained were
moderately-to-highly relevant to this patient population,
but also contributed several items that patients had not
ranked as meeting the relevance threshold (Table 4).
Three questions were removed by the investigators, from
the Index items listed in Table 4, during final item review.
An appetite item was dropped since it was redundant and
the direction of the phrasing was incompatible with the
other questions in the Index, all of which inquired about
declining health status. Another item on frequent urina-
tion was not included since it was linked in patient inter-
views to the result of surgery rather than the disease and
the positive nurse scoring of this item could also reflect
this treatment relationship. Similarly, an item on diarrhea
was also removed since its biological rationale was sus-
pect and poor bowel control could result from treatment.
Diarrhea did appear in the RCC literature review, how-
ever, and in some patient interviews was described as
occurring before diagnosis, although this involved a long
recall period. Given the confounding factors in this study,
further exploration of this issue was left for a follow-on
content confirmation study. The resulting Index covers
pain (4 items), breathing (1 item), weakness (1 item),
Table 3: Clinical Characteristic of RCC Patients, by Localized and Metastatic-Staged Disease
Localized (n = 14) Metastatic (n = 17)
Year of diagnosis, n (%)
2003 6 (42.9) 3 (17.6)
2002 8 (57.1) 5 (29.4)
2001 0 (0.0) 4 (23.5)
2000 0 (0.0) 2 (11.8)
1999 or earlier 0 (0.0) 3 (17.6)
Last treatment, n (%)
Surgery 14 (100) 6 (35.3)
Biological agents 0 (0.0) 8 (47.1)
Chemotherapy 0 (0.0) 1 (5.9)
Other 0 (0.0) 2 (11.8)
Months since last treatment: mean (SD), 8.6 (4.5) 6.0 (14.1)
median, [range] 8.5 [3.0–15.0] 1.0 [0.0–58.0]
All data patient-reported at time of interview. Percentages may not equal 100 due to rounding.Health and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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mood (4 items), sleep (1 item), weight loss (1 item), cog-
nitive functioning (2 items), fatigue (5 items), appetite (2
items), incontinence (2 items bowel and 2 items bladder),
and other constitutional symptoms (5 items; Table 5).
Discussion
The RCC Symptom Index was developed through a struc-
tured, iterative process that drew upon several informa-
tion sources to identify the appropriate signs and
symptoms. A broad range of physiological and psycholog-
ical disease manifestations were identified and found rel-
evant by a national, US cohort of RCC patients who were
undoubtedly treated at different cancer centers.
Consistent with the medical literature review, the most
common symptoms that initially led patients to seek
Table 4: RCC Index Mean Relevancy Item Scores of RCC Patients and Clinicians1
Item Patient Ratings Clinician Ratings
Localized Metastatic Total Nurse Physician Total
PAIN
I have pain 2.4 1.8 2.1 3.8 4.0 3.9
Pain interfered with my daily activities 2.0 1.8 1.9 3.8 3.2 3.5
I have pain in my back 2.0 1.1 1.5 2.4 2.6 2.5
I have discomfort or pain in my stomach area 1.7 1.8 1.8 2.6 1.8 2.2
BREATHING
I have been short of breath 0.7 2.5 1.7 3.8 3.0 3.3
WEAKNESS
I have felt weak 2.2 2.8 2.5 4.0 3.6 3.8
MOOD
I worry that my condition will get worse 3.0 3.1 3.1 3.6 2.4 3.0
I have emotional ups and downs 2.6 2.2 2.4 3.6 1.6 2.6
I feel depressed 2.6 2.0 2.3 3.6 1.8 2.7
I am able to enjoy life2 2.2 2.8 2.5 3.8 3.0 3.4
SLEEP
I have had trouble sleeping 2.5 2.1 2.3 3.6 2.4 3.0
WEIGHT LOSS
I am losing weight 1.4 2.0 1.7 3.5 3.6 3.6
COGNITIVE
I have difficulty remembering things 1.6 1.6 1.6 3.5 2.0 2.7
I have trouble concentrating 1.7 2.1 1.9 3.5 2.0 2.7
FATIGUE
I feel fatigued 2.3 2.0 2.2 3.8 3.8 3.8
I have a lack of energy 2.4 2.5 2.5 3.8 3.2 3.4
I feel tired 2.3 2.1 2.2 3.8 3.0 3.3
I have trouble starting things because I am tired 1.7 2.1 1.9 3.0 2.0 2.5
I have trouble finishing things because I am tired 1.9 2.4 2.2 3.0 2.0 2.5
APPETITE
I have lacked appetite 1.5 1.9 1.7 3.6 3.6 3.6
I have a good appetite3 2.5 3.1 2.8 3.0 3.4 3.2
INCONTINENCE (BOWEL OR BLADDER)
I have control of my bowels4 2.4 2.5 2.5 2.2 1.6 1.9
I have trouble moving my bowels 1.6 1.3 1.5 3.6 2.2 2.9
I urinate more frequently than usual5 1.7 1.7 1.7 2.2 1.6 1.9
I have difficulty urinating 1.6 1.2 1.4 2.4 1.6 2.0
OTHER SYMPTOMS
I have had chills 1.4 1.8 1.6 3.4 2.6 3.0
I have had fevers 1.3 1.5 1.4 3.8 3.0 3.4
I have had sweats6 1.2 1.1 1.1 3.8 3.2 3.5
I feel lightheaded 1.6 1.7 1.6 2.8 2.6 2.7
I am bothered by blood in my urine7 n/a n/a n/a 2.0 2.8 2.4
1 Relevancy scores based on a scale of 0–4, where 0 indicated "not at all " relevant and 4 indicated "very much" (or highly) relevant.
2 "I am able to enjoy life" was slightly modified for clinicians for testing purposes; item tested was "I am content with the quality of my life right now".
3 Not included due to redundancy with the other appetite item and incompatible direction of question phrasing (positive).
4,5 Not included due to uncertainty regarding causation: disease or treatment, as well as biological rationale.
6 Modified from "I am bothered by sweating" for clarity and consistency with other items.
7 Relevancy ratings not available since item was included based on findings from patient interviewsHealth and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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medical attention were pain, fatigue, and urinary prob-
lems such as hematuria. Once diagnosed with RCC, both
groups of patients – those with metastasized disease and
those with localized disease who had undergone surgery
for their renal cancer – indicated a rather high prevalence
of symptoms. The symptoms most apparent among the
localized RCC patients included irritability, pain, fatigue,
worry, and sleep disturbance, while the metastatic-stage
patients also included symptoms related to treatment and
disease progression, including weakness and shortness of
breath.
In a large-scale study of 335 patients with RCC rand-
omized to subcutaneous interferon or medroxyprogester-
one [8], the most frequently reported symptoms at week 4
assessed by the Rotterdam Symptom Checklist included
tiredness (57%), lack of energy (53%), lack of appetite
(33%), dry mouth (27%), and flu-like symptoms (nausea
15% and shivering 13%). Similar symptoms were
reported in a study among 70 patients, 57 of whom had
RCC, receiving doses of pegylated interferon alpha-2B
administered subcutaneously for 4 weeks [13], including
fatigue (38%), pain (34%), weight loss (28%), and dysp-
nea (21%). Smaller studies (i.e., those with 55 or fewer
patients) produced similar results with respect to reported
symptoms [11,12,14-17,19].
There are several limitations to this study. First, the RCC
patients were a US convenience sample who self-reported
their disease stage (localized vs. metastatic). It is likely
that patients were unaware of their exact disease stage, and
some patients who reported localized disease may have
developed metastases following their nephrectomy [43].
The fact that several patients who reported localized RCC
also indicated continued pain is suggestive of disease pro-
gression. In addition, while metastatic patients were asked
about their symptoms in the last 7 days when completing
the questionnaire, patients with localized disease were
asked about symptoms prior to treatment since they can
be asymptomatic after surgery [43]. Localized patients
may not have recalled the symptom experience as accu-
rately as possible if a shorter recall period had been possi-
ble. Similarly, symptom recall could become confused
with post-surgical recovery, especially regarding pain and
fatigue. However, anchoring of the symptom questions to
what was undoubtedly a significant life event, i.e., renal
Table 5: Final RCC Index. Below is a list of statements that other people with your illness have said are important. Circle one (1) 
number per line to indicate how true each statement has been for you during the past 7 days.
Not at all A little bit Some-what Quite a bit Very much
I have pain 0 1 2 3 4
Pain interfered with my daily activities  0 1 2 3 4
I have pain in my back  0 1 2 3 4
I have discomfort or pain in my stomach area 0 1 2 3 4
I have a good appetite  0 1 2 3 4
I have control of my bowels  0 1 2 3 4
I urinate more frequently than usual  0 1 2 3 4
I have had chills 0 1 2 3 4
I have had fevers 0 1 2 3 4
I have had sweats 0 1 2 3 4
I feel lightheaded 0 1 2 3 4
I am bothered by blood in my urine 0 1 2 3 4
I am losing weight  0 1 2 3 4
I have trouble moving my bowels  0 1 2 3 4
I have been short of breath  0 1 2 3 4
I have felt weak 0 1 2 3 4
I have lacked appetite  0 1 2 3 4
I have difficulty urinating 0 1 2 3 4
I have had trouble sleeping  0 1 2 3 4
I feel fatigued  0 1 2 3 4
I have a lack of energy  0 1 2 3 4
I feel tired  0 1 2 3 4
I have trouble starting things because I am tired 0 1 2 3 4
I have trouble finishing things because I am tired 0 1 2 3 4
I have difficulty remembering things 0 1 2 3 4
I have trouble concentrating  0 1 2 3 4
I worry that my condition will get worse  0 1 2 3 4
I have emotional ups and downs  0 1 2 3 4
I feel depressed  0 1 2 3 4
I am able to enjoy life  0 1 2 3 4Health and Quality of Life Outcomes 2007, 5:34 http://www.hqlo.com/content/5/1/34
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cancer surgery, should have assisted with patient recall
[52,53].
Our finding that metastatic patients did not rate pain as
highly as localized patients was surprising given the liter-
ature associating pain with tumor progression [54]. Fewer
than 25% of patients with metastatic disease reported
"somewhat," "quite a bit," or "very much" for any single
pain item. However, the lower frequency of reported pain
among this subset of RCC patients may be due to concur-
rent pain treatment. Patients were not asked about their
pain medications when being interviewed, and pain may
have been better controlled among metastatic-stage
patients. In the RCC population as a whole, pain was one
of the most relevant symptoms; caregivers considered
pain the most significant symptom. Finally, RCC patients
who participated in the study were generally Caucasian
and well-educated. These findings may have limited
applicability to minority US populations and to those of
other countries, although several of the studies appearing
in the literature review contained these populations.
Despite these weaknesses, we believe that we were able to
capture the relevant symptoms associated with kidney
cancer since our findings are based on a synthesis of infor-
mation from multiple sources: literature review, com-
pleted pilot questionnaires, structured patient and
caregiver interviews, and clinician evaluation. The RCC
Symptom Index is a brief, easily-understood, self-admin-
istered instrument that covers pain, shortness of breath,
weakness, sleep, weight loss, cognitive functioning,
fatigue, appetite, incontinence, other constitutional
symptoms, and mood. The 7-day recall period is suffi-
ciently short to maximize accurate patient recall while
avoiding the possible loading effect of a "bad symptom
day" or short-term flare caused by variation in symptom
frequency, intensity, or duration. 
Systemic mechanisms such as cytokine dysregulation may
underline cancer pathogenesis and explain the diversity of
RCC symptoms [55,56].  Consequently, the content
breadth of the Index may make it more sensitive to the full
impact of systemic  therapies on RCC patient symptoms.
While this project was underway, a kidney cancer symp-
tom scale was published: the Functional Assessment of
Cancer Therapy-Kidney   Symptom Index (FKSI) [41].
Although the FKSI (15-items) is shorter than the RCC
Symptom Index it has considerable overlap in content
[41]. 
Conclusion
This study systematically developed the content of a RCC
patient symptom questionnaire using literature review,
caregiver observation and above all, the perspective of
patients with the disease. The questionnaire is brief yet
comprehensive since it incorporates patient-identified
signs and symptoms across the disease spectrum. Due to
this diverse range of signs and symptoms, the Index may
be a more sensitive measure of the disease than a general
cancer symptom questionnaire. The Index can be used
alone to measure RCC symptom burden with minimal
respondent burden, or with other more general cancer
instruments for a more comprehensive assessment of
patient-reported outcomes.
The FKSI and RCC Symptom Index are currently undergo-
ing comparative content validation in a cohort of 50 kid-
ney cancer patients from several US clinical sites. This
study has access to clinical information contained in the
patient medical chart and will produce a refined version
of a symptom questionnaire that should be applicable to
RCC and kidney cancer patients. Construct validation
research is needed on the performance of the resulting
questionnaire, especially regarding its responsiveness. The
applicability of the final version to multi-national popu-
lations requires further investigation. Last but not least,
defining a minimal, clinically meaningful improvement,
as well as worsening, during construct validation is critical
to providing practicing physicians, medical directors and
health policy makers with a useful HRQL tool.
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